Novartis Expands Alliance with Science 37 to Advance Virtual Clinical Trials Program

NovartisNovartis has announced an additional strategic alliance with Science 37, a leader in decentralized clinical trial technology and design, to initiate up to 10 new clinical trials over the next three years. The studies will blend virtual and traditional models, with increasing degrees of decentralization towards a mostly "site-less" model. Novartis was an early investor in Science 37 and together we have already initiated virtual trials for cluster headache, acne and nonalcoholic steatohepatitis (NASH).

Decentralized, or virtual, trials harness digital technology to allow some or all aspects of a clinical trial to be carried out at a participant's home or local physician's office, rather than at a central trial site such as a large hospital. The new Novartis decentralized trials are expected to begin later this year in the United States (US) in the areas of dermatology, neuroscience and oncology, leveraging Science 37's proprietary Network Oriented Research Assistant (NORA®) technology, which enables patients to participate in studies using mobile devices and telemedicine services. Through this alliance, the companies plan to apply Science 37's customized enterprise software to some of the leading clinical development programs of Novartis.

"Novartis aims to run studies in ways that overcome many of the barriers patients face when deciding whether or not to enroll in clinical trials, like long journeys or extensive time spent at hospitals or trial sites," said Rob Kowalski, ad interim Head of Global Drug Development and Chief Medical Officer. "With our shared vision of futuristic trials enabled by technology, we're excited to expand our collaboration with Science 37 to pioneer a new, patient-centric research model."

"In our experience to date, we have been impressed with the recruitment in the virtual trial setup and believe for many patient populations this will be superior to traditional hospital or clinic sites," said Evan Beckman, Head of Translational Medicine at the Novartis Institutes for BioMedical Research. "Remote participation in research has the benefit of improving the breadth of participation from wider community and socio-economic backgrounds, while also allowing us to gather more meaningful real-world evidence in our clinical trials."

According to the Center for Information & Study on Clinical Research Participation (CISCRP), only 2% of the eligible population in the US participate in clinical trials. Those who do participate attend an average of 11 trial site visits in six months, representing a significant burden for both patients and trial centers. By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers. This approach also has the potential to increase the reach of our leading drug development and clinical trials enterprise into under-represented and underserved populations around the world, improving the caliber and quantity of data available to aid in drug discovery and development.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

Most Popular Now

Bayer Accelerates Six New Startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies from Canada...

Cerner Teams-Up with North London Partne…

Cerner has announced a new collaboration with North London Partners (NLP) - a partnership of health and care organisations across five London boroughs - to connect care information, share records...

Artificial Intelligence could Help Tackl…

Scientist from King’s College London believe that Artificial Intelligence could hold the key to identifying the best way to treat the country’s biggest killer, coronary heart disease (CHD). And now...

Researchers Use AI to Successfully Treat…

A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to successfully treat a patient with advanced cancer, completely...

Greater Manchester Health and Social Car…

Greater Manchester Health and Social Care Partnership(GMHSC Partnership) aims to deliver rapid savings and identify how the cloud can support the region’s devolved vision for integratedhealth and careservices through work...

Philips Launches New Cardiac Ultrasound …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the EPIQ CVx cardiovascular ultrasound system. Built on the powerful EPIQ ultrasound platform, EPIQ CVx is...

Orion Health Secures Place on Framework …

Orion Health has secured a place on a framework contract that will give health and care organisations easier access to the technology they need to deliver the NHS reform agenda...

Nottingham University Hospitals Switches…

Nottingham University Hospitals NHS Trust has completed a complex project to switch integration engines; on time, on budget, and with no disruption to services. The trust has a well-advanced 'best...

An Avatar Uses Your Gait to Predict How …

Humans instinctively adopt the gait that requires the least amount of energy given the walking conditions. Without realizing it, we are constantly tweaking our pace, stride length and foot lift...

Study on Cross-Border Health Services: E…

The overall objective of this study was to propose recommendations for improving the current level of information provision to patients by National Contact Points (NCPs). The research methodology used in...

Social Media in the Pharmaceutical Indus…

21 - 23 January 2019, London, UK. SMi Group are delighted to present the return of their 11th annual Social Media in the Pharmaceutical Industry conference to London on the 21st...

Kids Connect with Robot Reading Partners

Kids learn better with a friend. They're more enthusiastic and understand more if they dig into a subject with a companion. But what if that companion is artificial? Researchers at...